NASDAQ:BridgeBio Pharma, Inc.
График котировок BridgeBio Pharma, Inc.
График BBIO предоставлен TradingView
Добавить в список сравнения
Добавить в список отслеживания
Добавить в портфель
Основные параметры
P/S | 435.81 |
---|---|
P/BV | 16.41 |
EV/EBITDA | -19.23 |
Цена ао | 64.28 |
Основные владельцы
Institutions | Объем | Доля, % |
---|---|---|
AIG Asset Management (U.S), LLC | 5576380 | 4.54 |
Aisling Capital Management LP | 3989412 | 3.25 |
Kohlberg Kravis Roberts & Co LP | 34510971 | 28.13 |
SC US (TTGP), LTD. | 2544738 | 2.08 |
BlackRock Fund Advisors | 8099277 | 6.6 |
Perceptive Advisors LLC | 6706268 | 5.46 |
Viking Global Investors LP | 26620991 | 21.69 |
Cormorant Asset Management, LLC | 2265762 | 1.85 |
Nicholas Investment Partners | 24745 | 0.02 |
Pacific Life Fund Advisors LLC (PLFA) | 159277 | 0.13 |
Fernwood Investment Management, LLC | 143835 | 0.12 |
CT Mason | 73425 | 0.06 |
Janus Capital Management LLC | 1840285 | 1.5 |
Defiance ETFs, LLC | 4435 | 0 |
Bayview Asset Management Co., Ltd. | 35200 | 0.03 |
Ohio National Investments Inc | 73494 | 0.06 |
Baillie Gifford Investment Management (Europe) Limited | 23314 | 0.02 |
Northern Trust Investments Inc | 1346837 | 1.1 |
Hillhouse Capital Advisors, Ltd. | 4711604 | 3.84 |
Rockefeller & Co. LLC | 117235 | 0.1 |
WCM Investment Management, LLC | 6378 | 0.01 |
UBS Asset Management (Americas) Inc | 32157 | 0.03 |
Kohlberg Kravis Roberts & Co LP | 34510971 | 28.12 |
Donoghue Forlines LLC | 24712 | 0.02 |
BAMCO Inc | 25876 | 0.02 |
AMG Funds LLC | 179505 | 0.15 |
American Century Investment Management, Inc | 657864 | 0.54 |
Nicholas Investment Partners LP | 32979 | 0.03 |
SSGA Funds Management Inc | 2900278 | 2.36 |
Содержится в ETF
ETF | Доля, % | Доходность за год, % |
---|---|---|
Defiance Nasdaq Junior Biotechnology ETF | 3.09 |
Похожие компании
Описание BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; and collaboration with Salk Institute for Biological Studies. The company was founded in 2015 and is headquartered in Palo Alto, California.